GlassScriptPhysician profile
Lester Frederick Shalloway
NPI 1083689772
$9,637.46
in general payments reported to CMS, 2019-2025
61 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $1,160 · 2021: $1,820 · 2022: $1,397 · 2023: $1,335 · 2024: $1,052 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,741.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,130.20 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $763.49 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $702.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $686.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $587.34 | 2019-2025 | |
| Amgen INC. | $569.38 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Abbvie INC. | $510.03 | 2019-2025 | Vraylar, Ubrelvy |
| Abbott Laboratories | $346.26 | 2021-2025 | Freestyle Libre 3, Infinity |
| Novartis Pharmaceuticals Corporation | $329.76 | 2019-2025 | |
| Antares Pharma, INC. | $311.89 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.25 | 2019-2025 | Synjardy, Jardiance, Ofev |
| Amarin Pharma, INC. | $242.75 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.29 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $168.17 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $166.43 | 2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Shalloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.